Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Savara, Inc. (SVRA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.38-6.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SVRA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain borrowing capacity at $105 million | The company increased its loan capacity to $105 million. | Intact | Borrowing capacity falls below $100 million | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making healthcare growth story, not an established earnings compounder. The long-term thesis is in a watch state, with low confidence because recent financial performance is weak relative to its industry cohort.
The evidence snapshot provides no valuation or market-expectations data, so whether SVRA is cheap, fair, or expensive cannot be assessed. It also does not show what investors already assume about future growth or profitability.
Near-term fundamentals face pressure: operating and net losses widened from 2025-Q3 to 2026-Q2, and the evidence flags an elevated risk of another earnings miss. The $105 million term loan is intended to support growth and operations, but current results show limited progress toward profitability; the recent FDA approval is a positive event, though its financial effect is not provided.
Over the next few quarters, the thesis depends on execution and whether losses begin to improve without guidance cuts. A weakening jobs trend could add pressure through recession concerns, while continued strength among Healthcare bellwethers such as VRTX, REGN, and MRNA could support sector momentum. The effects of the leadership change and the new office lease are not yet established.
The 1-to-3-year view remains uncertain: the FDA approval and stronger sector backdrop are constructive, but widening losses, earnings-miss risk, and limited evidence of improved profitability weigh on the thesis. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| It plans to move its headquarters by July 2026. |
| Intact |
| Relocation not completed by Q3 2026 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
FDA approval of Molbreevi for autoimmune PAP | A primary condition in Savara, Inc.'s published investment case. The stated target is FDA approval received by end of 2027. | Under Pressure | FDA approval not granted by end of 2027 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.30 → $-0.39 · observed estimates
$0.08B → $0.08B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-07-25 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-07-26 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-07-27 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-07-28 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-07-29 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-07-30 | $-0.29 | $83,421,430 | 5 / 7 |
| 2026-07-31 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-01 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-02 | $-0.29 | $83,421,430 | 5 / 7 |
| 2026-08-03 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-04 | $-0.29 | $83,421,430 | 5 / 7 |
| 2026-08-05 | $-0.29 | $83,421,430 | 5 / 7 |
| 2026-08-06 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-08 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-09 | $-0.29 | $83,421,430 | 5 / 7 |
| 2026-08-10 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-12 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-13 | $-0.29 | $83,421,430 | 5 / 7 |
| 2026-08-14 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-15 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-16 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-17 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-18 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-19 | $-0.30 | $83,421,429 | 5 / 5 |
| 2026-08-20 | $-0.36 | $80,634,000 | 5 / 5 |
| 2026-08-21 | $-0.36 | $80,634,000 | 5 / 5 |
| 2026-08-22 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-08-23 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-08-24 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-08-25 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-08-26 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-08-27 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-08-28 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-08-29 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-08-30 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-08-31 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-01 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-02 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-03 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-04 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-05 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-06 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-07 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-08 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-09 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-10 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-11 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-12 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-13 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-14 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-15 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-16 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-17 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-18 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-19 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-20 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-21 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-22 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-23 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-24 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-25 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-26 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-27 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-28 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-29 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-09-30 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-10-01 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-10-02 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-10-03 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-10-04 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-10-05 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-10-06 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-10-07 | $-0.36 | $80,637,375 | 5 / 5 |
| 2026-10-08 | $-0.39 | $79,677,667 | 5 / 6 |
| 2026-10-09 | $-0.39 | $79,677,667 | 5 / 6 |
| 2026-10-10 | $-0.39 | $79,677,667 | 5 / 6 |
| 2026-10-11 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-12 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-13 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-14 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-15 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-16 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-17 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-18 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-19 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-20 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-21 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-22 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-23 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-24 | $-0.39 | $79,677,667 | 6 / 6 |
| 2026-10-25 | $-0.39 | $79,677,667 | 6 / 7 |
| 2026-10-26 | $-0.39 | $79,677,667 | 6 / 7 |
| 2026-10-27 | $-0.39 | $79,677,667 | 6 / 7 |
| 2026-10-28 | $-0.39 | $79,675,111 | 6 / 7 |
| 2026-10-29 | $-0.39 | $79,675,111 | 6 / 7 |
| 2026-10-30 | $-0.39 | $79,675,111 | 6 / 7 |
| 2026-10-31 | $-0.39 | $79,675,111 | 6 / 7 |
| 2026-11-01 | $-0.39 | $79,675,111 | 6 / 7 |
| 2026-11-02 | $-0.39 | $79,675,111 | 6 / 7 |
| 2026-11-03 | $-0.39 | $79,675,111 | 6 / 7 |
| 2026-11-04 | $-0.39 | $79,675,111 | 6 / 7 |
| 2026-11-05 | $-0.39 | $79,675,111 | 6 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 9 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.